risperidone has been researched along with Neuronal Ceroid-Lipofuscinoses in 2 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Neuronal Ceroid-Lipofuscinoses: A group of severe neurodegenerative diseases characterized by intracellular accumulation of autofluorescent wax-like lipid materials (CEROID; LIPOFUSCIN) in neurons. There are several subtypes based on mutations of the various genes, time of disease onset, and severity of the neurological defects such as progressive DEMENTIA; SEIZURES; and visual failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects." | 7.72 | Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. ( Buyse, GM; Proost, JE; Van Hove, JL; Vercammen, L, 2003) |
| "We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects." | 3.72 | Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy. ( Buyse, GM; Proost, JE; Van Hove, JL; Vercammen, L, 2003) |
| "Patients with juvenile neuronal ceroid lipofuscinosis (JNCL) often have severe psychiatric symptoms." | 2.70 | New antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses--a pilot study. ( Aberg, LE; Aronen, ET; Bäckman, ML; Santavuori, PR, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vercammen, L | 1 |
| Buyse, GM | 1 |
| Proost, JE | 1 |
| Van Hove, JL | 1 |
| Bäckman, ML | 1 |
| Aberg, LE | 1 |
| Aronen, ET | 1 |
| Santavuori, PR | 1 |
1 trial available for risperidone and Neuronal Ceroid-Lipofuscinoses
| Article | Year |
|---|---|
New antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses--a pilot study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; | 2001 |
1 other study available for risperidone and Neuronal Ceroid-Lipofuscinoses
| Article | Year |
|---|---|
Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy.
Topics: Adult; Antipsychotic Agents; Creatine Kinase; Dopamine; Female; Fever; Hallucinations; Humans; Intel | 2003 |